Delivery Order SPE2DR25D3103-SPE2DR26F0B3N
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 29, 2025, for the supply of Atovaquone-Proguanil 250-100mg tablets (100 count) with a ceiling value of $7,348.24. This firm fixed-price delivery order, with an ultimate completion date of December 30, 2025, represents a non-competitive set-aside award executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999.99 million through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Atovaquone-Proguanil 250-100mg tablets (100-count units) with a ceiling value of $6,804.82. This is a firm fixed-price delivery order under a competitive, non-set-aside procurement. The order has an ultimate completion date of September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Atovaquone-Proguanil 250-100 tablets (100 count) valued at $2,814.68. This is a firm fixed-price delivery order with no set-aside designation, meaning the award was competitively procured on a full and open basis. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a completion date of January 8, 2026. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Atovaquone-Proguanil 250-100 mg tablets in quantities of 100 units, with a contract ceiling value of $27,644.83. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is scheduled for ultimate completion by November 10, 2025, and will be performed at the contractor's Corporate Office...
- The Defense Logistics Agency awarded a $14,922.01 delivery order to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 (100 tablets) on September 12, 2025, with a completion date of September 15, 2025. This is a firm fixed price order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Atovaquone-Proguanil 250-100 tablets in a quantity of 100 units, with a ceiling value of $1,343.16. This contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and represents a non-competitive set-aside transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $15,817.44 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) on December 4, 2025, with completion scheduled for December 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and...
- The Defense Logistics Agency awarded a delivery order valued at $2,167.20 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 mg tablets (100 count) on January 20, 2026, with completion scheduled for January 21, 2026. This is a firm fixed-price delivery order issued without a set-aside designation, indicating competitive award based on full and open competition. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $1,490.07 to Amerisourcebergen Drug Corp for Atovaquone-Proguanil 250-100 milligram tablets (100 count) on January 23, 2026, with an ultimate completion date of January 26, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Amerisourcebergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,492.71 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) on November 4, 2025, with completion scheduled for November 5, 2025. This non-competitive delivery order utilizes firm fixed-price terms and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F0B3NDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp (a subsidiary of parent company Cencora, Inc.) on February 4, 2026, for the supply of Atovaquone-Proguanil 250-100 100S tablets, with a contract ceiling value of $16,064.57. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of February 5, 2026. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. That prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of medications, vaccines, and medical supplies to military healthcare programs worldwide. AmerisourceBergen has demonstrated significant capability in meeting federal pharmaceutical procurement requirements, and Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and treatment in military and defense healthcare settings.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 2/3/26 |